The rise of Viagra and its effect on the medicinal landscape presents a complex question for investors. While the first sales statistics were astounding, the intellectual property has lapsed, leading to a deluge of generic alternatives that are chipping away at profit. Moreover, the market is facing challenges related to aging trends and shifting h